Evidence in favour
- 18 distinct acquisition events survive duplicate and security-type controls.
- Participation spans 13 named insiders rather than one filing source.
- The latest qualifying evidence is fresh, dated 08 Sep 2026.
Company insider dossier
Roivant Sciences Ltd insider intelligence
ROIV filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
53/100
Balanced insider tape
96/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 8 Sep 2026
Investment committee read
Balanced insider tape
Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.
Wait for clearer clusteringDecision risks
- Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 40.82 USD
- One-week move
- +16.9%
- Four-week move
- +12.8%
- Fair-value gap
- +150.4%
- Trend signal
- Active
- Relative strength
- 39.1
Directional balance
Controlled event mix
28.6%acquisition
- Acquisition events
- 18
- Disposal events
- 45
- Net value
- -$327.3M
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
2029 Jun
006 Jul
313 Jul
020 Jul
327 Jul
003 Aug
310 Aug
1917 Aug
424 Aug
031 Aug
307 Sep
014 Sep
Named participants
Insider conviction by person
FITZGERALD, MEGHANDirector646 events
SUKHATME, MAYUKHDirector, President & CIO6221 events
EPPERLY, MELISSA B,Director543 events
VENKER, ERICPresident & Immunovant CEO5314 events
MOMTAZEE, JAMES CDirector281 events
OREN, ILANDirector281 events
TORTI, FRANKPresident and Vant Chair252 events
HUMES, JENNIFERChief Accounting Officer252 events
PULIK, RICHARDCFO223 events
GLINE, MATTHEWDirector, CEO204 events
GOLD, DANIEL ALLENDirector195 events
QVT, FINANCIAL LPDirector by Deputization195 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable ROIV filing ledger
Showing 1 to 30 of 104.
FITZGERALD, MEGHANDirector
DisposalOptions and derivatives
20000 sharesStock Option (Right to Buy)
Not reportedContext evidence
FITZGERALD, MEGHANDirector
DisposalCommon equity
20000 sharesCommon Shares
$798.0KDirectional evidence
FITZGERALD, MEGHANDirector
AcquisitionCommon equity
20000 sharesCommon Shares
$176.0KDirectional evidence
VENKER, ERICPresident & Immunovant CEO
DisposalOptions and derivatives
200000 sharesStock Option (Right to Buy)
Not reportedContext evidence
VENKER, ERICPresident & Immunovant CEO
DisposalCommon equity
166182 sharesCommon Shares
$5.9MDirectional evidence
VENKER, ERICPresident & Immunovant CEO
DisposalCommon equity
33818 sharesCommon Shares
$1.2MDirectional evidence
VENKER, ERICPresident & Immunovant CEO
AcquisitionCommon equity
200000 sharesCommon Shares
$770.0KDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalOptions and derivatives
144756 sharesStock Option (Right to Buy)
Not reportedContext evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
144756 sharesCommon Shares
$5.3MDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
AcquisitionCommon equity
144756 sharesCommon Shares
$557.3KDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalOptions and derivatives
17519 sharesStock Option (Right to Buy)
Not reportedContext evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
17519 sharesCommon Shares
$653.5KDirectional evidence
VENKER, ERICPresident & Immunovant CEO
DisposalCommon equity
13909 sharesCommon Shares
$512.4KDirectional evidence
PULIK, RICHARDCFO
DisposalCommon equity
5749 sharesCommon Shares
$211.8KDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
AcquisitionCommon equity
17519 sharesCommon Shares
$67.4KDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalOptions and derivatives
172899 sharesStock Option (Right to Buy)
Not reportedContext evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
172899 sharesCommon Shares
$6.4MDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
AcquisitionCommon equity
172899 sharesCommon Shares
$665.7KDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
136942 sharesCommon Shares
Not reportedContext evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
105141 sharesCommon Shares
$3.8MDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
31801 sharesCommon Shares
$1.2MDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
AcquisitionCommon equity
105141 sharesCommon Shares
$404.8KDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
AcquisitionCommon equity
31801 sharesCommon Shares
$122.4KDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
284707 sharesCommon Shares
Not reportedContext evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
284707 sharesCommon Shares
$10.3MDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
AcquisitionCommon equity
284707 sharesCommon Shares
$1.1MDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
243177 sharesCommon Shares
Not reportedContext evidence
SUKHATME, MAYUKHDirector, President & CIO
DisposalCommon equity
243177 sharesCommon Shares
$8.8MDirectional evidence
SUKHATME, MAYUKHDirector, President & CIO
AcquisitionCommon equity
243177 sharesCommon Shares
$936.2KDirectional evidence
VENKER, ERICPresident & Immunovant CEO
DisposalOptions and derivatives
200000 sharesStock Option (Right to Buy)
Not reportedContext evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.